share_log

Credit Suisse Maintains Outperform on Pear Therapeutics, Lowers Price Target to $9

Credit Suisse Maintains Outperform on Pear Therapeutics, Lowers Price Target to $9

瑞士信貸維持Pear Therapeutics的跑贏大盤,將目標股價下調至9美元
Benzinga Real-time News ·  2022/07/26 09:24

Credit Suisse analyst Judah Frommer maintains Pear Therapeutics (NASDAQ:PEAR) with a Outperform and lowers the price target from $11 to $9.

瑞士信貸分析師猶大·弗羅默維持Pear Therapeutics(納斯達克股票代碼:PEAR)的跑贏大盤,並將目標股價從11美元下調至9美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論